Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Selling a new chemistry platform to the conservative pharmaceutical industry is incredibly difficult. Value is only demonstrated when the novel chemistry is used to solve a specific, high-value biological problem that is intractable with conventional methods, thereby proving its unique power.

Many peptides are unlikely to ever receive FDA approval because their simple, easily replicated structures make them commodities. Pharma companies won't fund billion-dollar trials for drugs they can't patent, leaving them in a permanent gray market.

Despite claims of interest in early-stage innovation, big pharma companies typically wait for significant de-risking before acquiring or partnering. BGV's founder observes that real interest usually materializes only after Phase 2A data, forcing venture-backed biotechs to carry assets further than acquirers' stated appetites suggest.

Martin Shkreli claims that from a pharmaceutical development perspective, peptides are often avoided. They possess inherent weaknesses, being more complex than small molecules but less effective than large molecules like antibodies. This makes their recent popularity in biohacking circles ironic to industry insiders.

Turbine's pharma partners consistently praised the deep biological competence of its science team. This ability to engage as scientific peers, not just data scientists, built essential trust for early deals when the AI platform was still largely unvalidated.

According to Novartis's CEO, a top reason for rejecting potential biotech partners is their underinvestment in Chemistry, Manufacturing, and Controls (CMC). Startups often neglect this unglamorous work, leading to deal failure because the acquirer can't be sure the drug can be scaled efficiently and safely.

When seeking partnerships, biotechs should structure their narrative around three core questions pharma asks: What is the modality? How does the mechanism work? And most importantly, why is this the best differentiated approach to solve a specific clinical challenge and fit into the competitive landscape?

Martin Shkreli argues the pharmaceutical industry avoids peptides due to inherent weaknesses like short half-lives, viewing them as the 'worst of both worlds' compared to small molecules or antibodies. This perspective reframes the peptide craze as an elevation of a scientifically challenging and often impractical drug class.